Core Viewpoint - Xiangyu Medical is a leading enterprise in the domestic rehabilitation medical device industry, with a comprehensive product range and a focus on innovation in new business areas like brain-computer interfaces [1][6]. Group 1: Company Overview - Xiangyu Medical was established on March 20, 2002, and was listed on the Shanghai Stock Exchange on March 31, 2021, with its headquarters in Anyang, Henan Province [1]. - The company has developed a full industry chain layout, covering 10 major categories, 55 series, and thousands of products in the rehabilitation medical device sector [1]. Group 2: Financial Performance - For Q3 2025, Xiangyu Medical reported revenue of 537 million yuan, ranking 22nd out of 42 in the industry, significantly lower than the top competitors, Mindray Medical and United Imaging Medical, which reported revenues of 25.83 billion yuan and 8.86 billion yuan, respectively [2]. - The company's net profit for the same period was 41.91 million yuan, ranking 24th in the industry, again trailing behind major players [2]. Group 3: Financial Ratios - As of Q3 2025, Xiangyu Medical's debt-to-asset ratio was 37.63%, higher than the previous year's 27.15% and above the industry average of 27.21% [3]. - The gross profit margin for the same period was 67.19%, an increase from 66.86% year-on-year and above the industry average of 48.67% [3]. Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 51.24% to 9,531, while the average number of shares held per shareholder decreased by 33.88% to 16,800 shares [5]. Group 5: Strategic Outlook - According to CITIC Securities, Xiangyu Medical is expected to see a steady recovery in traditional rehabilitation business in Q3 and Q4, with new revenue contributions from brain-computer interface projects [6]. - The company is positioned to benefit from policy support and aging population demands, with forecasts for revenue growth of 13.03%, 14.20%, and 11.27% from 2025 to 2027 [6].

Core Viewpoint - Xiangyu Medical (688626.SH) reported a year-on-year increase in operating revenue for Q3 2025, but experienced a significant decline in net profit attributable to shareholders [1] Financial Performance - Operating revenue for Q3 2025 reached 178 million yuan, representing a year-on-year increase of 5.46% [1] - Net profit attributable to shareholders was 8.59 million yuan, showing a year-on-year decrease of 48.82% [1] - Net profit attributable to shareholders after deducting non-recurring gains and losses was 6.91 million yuan, down 37.21% year-on-year [1]

Group 1 - The core point of the article is that Xiangyu Medical (SH 688626) held its third board meeting on October 30, 2025, to review the proposal for the company's Q3 2025 report [1] - For the year 2024, Xiangyu Medical's revenue composition is 98.67% from medical devices and 1.33% from other businesses [1] - As of the report, Xiangyu Medical has a market capitalization of 8.7 billion yuan [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025 年 11 月 11 日（星期二）13:00-14:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com） 证券代码：688626 证券简称：翔宇医疗 公告编号：2025-053 河南翔宇医疗设备股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 会议召开方式：上证路演中心网络文字互动 投资者可于 2025 年 11 月 3 日（星期一）至 11 月 10 日（星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 xymedical@xyyl.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 河南翔宇医疗设备股份有限公司（以下简称"公司"）已于 2025 年 10 月 31 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果 ...

证券代码：688626 证券简称：翔宇医疗 公告编号：2025-051 河南翔宇医疗设备股份有限公司 关于取消监事会、修订《公司章程》并办理工商变更 登记及修订、制定公司部分治理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 河南翔宇医疗设备股份有限公司（以下简称"公司"）于 2025 年 10 月 30 日召开第三届董事会第七次会议、第三届监事会第七次会议，审议通过了《关于 取消监事会、修订〈公司章程〉并办理工商变更登记的议案》《关于修订、制定 公司部分治理制度的议案》。现将相关情况公告如下： 一、关于取消公司监事会的相关情况 根据《公司法》《关于新<公司法>配套制度规则实施相关过渡期安排》《上 市公司章程指引》等法律、行政法规、部门规章的规定，同时结合公司实际情况， 公司董事会增加 1 名职工代表董事，董事会人数由 5 名调整为 6 名，不再设置监 事会、监事会主席及其他监事，由董事会审计委员会行使《公司法》规定的监事 会的职权。自公司股东大会审议通过取消监事会事项之日起，公司监事会予以取 消，免去监事会主 ...

证券代码：688626 证券简称：翔宇医疗 公告编号：2025-052 河南翔宇医疗设备股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第二次临时股东大会 召开日期时间：2025 年 11 月 24 日 14 点 00 分 召开地点：河南省安阳市内黄县帝喾大道中段公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 11 月 24 日 至2025 年 11 月 24 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通 股东大会召开日期：2025年11月24日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股 ...

证券代码：688626 证券简称：翔宇医疗 公告编号：2025-050 河南翔宇医疗设备股份有限公司 第三届监事会第七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 河南翔宇医疗设备股份有限公司（以下简称"公司"）第三届监事会第七次 会议于 2025 年 10 月 30 日在公司会议室以现场的方式召开。会议通知已于 2025 年 10 月 25 日送达各位监事。本次会议应出席监事 3 人，实际出席监事 3 人。会 议由监事会主席李治锋先生主持。会议的召开及表决程序符合有关法律、行政法 规、部门规章和《公司章程》的规定。 经审议，监事会认为：公司 2025 年第三季度报告的编制和审议程序符合相 关法律法规和《公司章程》等内部规章制度的规定。报告的内容与格式符合相关 规定，报告内容真实、准确、完整地反映了公司 2025 年第三季度的财务状况、 经营成果及现金流量等事项，不存在任何虚假记载、误导性陈述或者重大遗漏。 报告编制过程中，未发现参与报告编制和审议的人员有违反保密规定的行为。 表决 ...

证券代码：688626 证券简称：翔宇医疗 公告编号：2025-049 河南翔宇医疗设备股份有限公司 第三届董事会第七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 河南翔宇医疗设备股份有限公司（以下简称"公司"）第三届董事会第七次 会议于 2025 年 10 月 30 日在公司会议室以现场结合通讯的方式召开。会议通知 已于 2025 年 10 月 25 日送达各位董事。本次会议应出席董事 5 人，实际出席董 事 5 人。会议由董事长何永正先生召集并主持，公司监事及高级管理人员列席会 议。会议的召开及表决程序符合有关法律、行政法规、部门规章和《公司章程》 的规定。 二、董事会会议审议情况 经与会董事投票表决，本次会议审议并通过了以下议案： （一）审议通过《关于公司 2025 年第三季度报告的议案》 公司 2025 年第三季度报告的编制和审议程序符合相关法律法规和《公司章 程》等内部规章制度的规定。报告的内容与格式符合相关规定，报告内容真实、 准确、完整地反映了公司 2025 年第三季 ...

Financial Performance - The company's operating revenue for the third quarter was ¥177,983,291.97, an increase of 5.46% compared to the same period last year[4]. - The total profit for the quarter decreased by 71.05% to ¥5,236,453.20, while the net profit attributable to shareholders fell by 48.82% to ¥8,586,869.79[4][8]. - The basic earnings per share for the quarter was ¥0.06, down 45.45% from the same period last year[4][8]. - The company's total profit for the year-to-date period decreased by 44.06% to ¥44,305,425.87[4][8]. - Net profit for the first three quarters of 2025 was ¥41,907,442.75, a decrease of 43% from ¥73,382,295.90 in the previous year[22]. - Basic earnings per share for the period was ¥0.29, down from ¥0.47 in the same period last year[23]. Research and Development - Research and development expenses amounted to ¥49,094,672.85, representing 27.58% of operating revenue, an increase of 4.80 percentage points year-on-year[5]. - Research and development expenses rose to ¥125,479,123.87, an increase of 20.5% compared to ¥104,122,259.04 in 2024[21]. - The company achieved a total of 387 medical device registration certificates and filings, with 10 new additions during the reporting period[12]. - The company obtained 87 new patents, including 30 invention patents, bringing the total to 1,936 patents[12]. - The company has accumulated 2,340 intellectual property rights, including 1,070 utility model patents[14]. Assets and Liabilities - The total assets of the company increased by 11.76% to ¥3,272,197,143.87 compared to the end of the previous year[5]. - Total assets increased to ¥3,272,197,143.87, compared to ¥2,927,874,338.81 at the end of the previous year[19]. - Total liabilities rose to ¥1,231,446,217.25, up from ¥873,096,802.37 year-over-year[19]. - The company's equity attributable to shareholders decreased to ¥2,026,726,626.27 from ¥2,038,679,134.12 in the previous year[19]. Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥71,197,504.58, a decrease of 23.43% compared to the previous year[4]. - Cash inflow from operating activities for the first three quarters of 2025 was $693.38 million, an increase of 8.8% compared to $637.26 million in the same period of 2024[25]. - Net cash flow from operating activities decreased to $71.20 million in 2025 from $92.98 million in 2024, reflecting a decline of 23.5%[25]. - Total cash inflow from investment activities was $106.16 million in 2025, significantly lower than $324.26 million in 2024, marking a decrease of 67.2%[26]. - Net cash flow from investment activities was -$295.11 million in 2025, worsening from -$186.98 million in 2024[26]. - Cash inflow from financing activities increased to $818.50 million in 2025, compared to $492.00 million in 2024, representing a growth of 66.3%[26]. - Net cash flow from financing activities was $255.14 million in 2025, up from $151.23 million in 2024, indicating a rise of 68.7%[26]. - The ending cash and cash equivalents balance for 2025 was $734.13 million, compared to $709.13 million in 2024, showing an increase of 3.5%[26]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 9,531[10]. - The largest shareholder, Henan Xiangyu Health Industry Management Co., Ltd., holds 56.43% of the shares[10]. - The company has a total of 90,286,560 shares held by Henan Xiangyu Health Industry Management Co., Ltd., representing a significant shareholder[11]. Achievements and Recognition - The company successfully led a major scientific project in Henan Province focused on key technologies for traditional Chinese medicine therapy robots[12]. - The company was awarded the third prize in military scientific and technological progress[13]. - The company has been recognized as a member of the Brain-Computer Interface Technology Innovation and Industry Service Alliance[13]. - The company’s intelligent workshop for rehabilitation medical devices was rated as a smart workshop in Henan Province for 2025[13].

河南翔宇医疗设备股份有限公司 防范控股股东、实际控制人及其关联方占用公司资金的制度 第一章 总则 第二章 防范资金占用的原则 第四条 公司与控股股东、实际控制人及其关联方发生的经营性资金往来, 应当严格 履行相关审议程序和信息披露义务，明确经营性资金往来的结算期限，不得 以经营性资金往来的形式变相为控股股东、实际控制人及其关联方提供资金 等财务资助。 第三章 责任与措施 第一条 为建立防范控股股东、实际控制人及其关联方占用河南翔宇医疗设备股份有 限公司(以下简称"公司")资金的长效机制, 杜绝控股股东、实际控制人及其 关联方资金占用行为的发生, 根据《公司法》《证券法》《上市公司监管指 引第 8 号——上市公司资金往来、对外担保的监管要求》《上海证券交易所 科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关法律、法规及规范性文件的要求以及《河南翔宇医 疗设备股份有限公司章程》(以下简称"公司章程")、《河南翔宇医疗设备 股份有限公司关联交易决策制度》的有关规定, 特制定本制度。 第二条 本制度所称资金占用包括但不限于: 经营性资金占用和非经营性资金占用。 经营性资金占 ...